NCT04895735: MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 45 taking part
- Started
- 23 Jul 2021
- Primary completion
- 13 Aug 2025
- Arms
- Treatment (pembrolizumab, pemetrexed)
- Results
- Posted on the registry
- 20 May 2021: Trial registered
- 23 Jul 2021: Trial started
- 4 Jun 2026: Trial results posted
Posted results
The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.
Confirmed Response Rate
Primary outcome · Number, proportion of participants · 24 weeks
| Group | Analysed | Value |
|---|---|---|
| Cohort A (Adenoid Cystic Carcinoma) | 11 | 0 (95% Confidence Interval 0 to 0.28) |
| Cohort A1 (ACC Patients Enrolled Starting With MCCC Amendment 3) | 9 | 0.11 (95% Confidence Interval 0 to 0.48) |
| Cohort B (Non-adenoid Cystic Carcinoma) | 24 | 0.375 (95% Confidence Interval 0.19 to 0.59) |
Clinical Benefit Rate (CBR)
Primary outcome · Number, proportion of patients · 24 weeks
| Group | Analysed | Value |
|---|---|---|
| Cohort A | 11 | 0.727 (95% Confidence Interval 0.390 to 0.940) |
| Cohort A1 | 9 | 1.0 (95% Confidence Interval 0.664 to 1.0) |
| Cohort B (Non-adenoid Cystic Carcinoma) | 24 | 0.583 (95% Confidence Interval 0.366 to 0.779) |
Incidence of Adverse Events
Secondary outcome · Number of participants · 27 months
| Group | Analysed | Value |
|---|---|---|
| Cohort A | 11 | 8 |
| Cohort A1 | 9 | 8 |
| Cohort B (Non-adenoid Cystic Carcinoma) | 24 | 19 |